IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193
IDEAYA Biosciences, Inc. (IDYA) announced the FDA has completed its review of the Amgen-sponsored Investigational New Drug application and concluded that the proposed clinical study may proceed to evaluate IDE397 in combination with AMG 193 in solid tumors having MTAP deletion.